Tweet
Credit Suisse Group set a $40.00 price target on Aimmune Therapeutics (NASDAQ:AIMT) in a research note released on Monday, MarketBeat reports. The firm currently has a buy rating on the biotechnology company's stock.
Several other brokerages also recently weighed in on AIMT. Cantor Fitzgerald restated a buy rating and set a $64.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, May 9th. BidaskClub upgraded shares of Aimmune Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 17th. Wedbush restated an outperform rating and set a $72.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, May 30th. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a buy rating to a hold rating in a research report on Friday, May 11th. Finally, ValuEngine upgraded shares of Aimmune Therapeutics from a buy rating to a strong-buy rating in a research report on Tuesday, May 22nd. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $52.89. Get Aimmune Therapeutics alerts:
Shares of Aimmune Therapeutics stock opened at $27.90 on Monday. Aimmune Therapeutics has a 52-week low of $18.74 and a 52-week high of $42.00. The company has a market capitalization of $1.66 billion, a P/E ratio of -10.69 and a beta of -0.24. Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.05). equities research analysts forecast that Aimmune Therapeutics will post -3.53 EPS for the current fiscal year.
In related news, CFO Eric Bjerkholt acquired 1,600 shares of Aimmune Therapeutics stock in a transaction dated Wednesday, June 13th. The stock was acquired at an average price of $30.41 per share, for a total transaction of $48,656.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink . Also, insider Douglas T. Sheehy sold 3,296 shares of Aimmune Therapeutics stock in a transaction on Tuesday, May 22nd. The shares were sold at an average price of $33.00, for a total transaction of $108,768.00. The disclosure for this sale can be found here . Insiders have sold a total of 364,493 shares of company stock valued at $11,580,119 in the last 90 days. Insiders own 14.70% of the company's stock.
Several institutional investors have recently made changes to their positions in the company. Schroder Investment Management Group increased its holdings in shares of Aimmune Therapeutics by 50.2% in the 2nd quarter. Schroder Investment Management Group now owns 44,136 shares of the biotechnology company's stock valued at $1,207,000 after acquiring an additional 14,760 shares during the period. California Public Employees Retirement System increased its holdings in shares of Aimmune Therapeutics by 50.3% in the 2nd quarter. California Public Employees Retirement System now owns 58,455 shares of the biotechnology company's stock valued at $1,572,000 after acquiring an additional 19,560 shares during the period. MetLife Investment Advisors LLC increased its holdings in shares of Aimmune Therapeutics by 19.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 20,346 shares of the biotechnology company's stock valued at $547,000 after acquiring an additional 3,261 shares during the period. Metropolitan Life Insurance Co. NY increased its holdings in shares of Aimmune Therapeutics by 21.1% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 14,369 shares of the biotechnology company's stock valued at $386,000 after acquiring an additional 2,501 shares during the period. Finally, Ardsley Advisory Partners acquired a new position in shares of Aimmune Therapeutics in the 2nd quarter valued at $202,000. 80.16% of the stock is currently owned by institutional investors and hedge funds.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy